IMpower150

IMpower150 is a clinical trial that evaluates a combination of cancer treatments for advanced lung cancer patients. It tests whether adding certain targeted therapies and immunotherapies to standard chemotherapy improves outcomes, like delaying the progression of cancer or increasing survival rates. Specifically, it combines drugs that help the immune system recognize and attack tumors with chemotherapy, aiming to boost effectiveness for patients with stubborn or resistant types of lung cancer. The trial's goal is to determine if this combined approach offers better results than traditional treatments alone.